Insmed Target of Unusually Large Options Trading (INSM)

Insmed Incorporated (NASDAQ:INSM) was the recipient of some unusual options trading on Monday. Investors purchased 896 put options on the company. This is an increase of 679% compared to the typical daily volume of 115 put options.

Insmed (NASDAQ INSM) opened at $32.99 on Thursday. Insmed has a fifty-two week low of $11.49 and a fifty-two week high of $33.54. The company has a market capitalization of $2,530.00, a price-to-earnings ratio of -10.57 and a beta of 1.18. The company has a current ratio of 15.21, a quick ratio of 15.21 and a debt-to-equity ratio of 0.13.

A number of equities analysts have recently weighed in on the company. Zacks Investment Research lowered Insmed from a “hold” rating to a “sell” rating in a research note on Wednesday. BidaskClub raised Insmed from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Cowen reissued a “buy” rating and set a $54.00 price target on shares of Insmed in a research note on Friday, November 3rd. ValuEngine raised Insmed from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. Finally, Robert W. Baird reaffirmed a “positive” rating and issued a $32.00 price objective (up from $23.00) on shares of Insmed in a research note on Wednesday, September 6th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $34.50.

In related news, Director Donald J. Hayden, Jr. sold 15,000 shares of the company’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $32.50, for a total transaction of $487,500.00. Following the completion of the sale, the director now owns 71,131 shares in the company, valued at $2,311,757.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.10% of the company’s stock.

Several institutional investors have recently bought and sold shares of INSM. The Manufacturers Life Insurance Company lifted its position in Insmed by 0.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 49,163 shares of the biopharmaceutical company’s stock worth $844,000 after acquiring an additional 197 shares during the period. Legal & General Group Plc raised its stake in shares of Insmed by 2.0% during the 2nd quarter. Legal & General Group Plc now owns 20,173 shares of the biopharmaceutical company’s stock valued at $347,000 after buying an additional 390 shares during the last quarter. Parametric Portfolio Associates LLC raised its stake in shares of Insmed by 11.2% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 16,035 shares of the biopharmaceutical company’s stock valued at $275,000 after buying an additional 1,618 shares during the last quarter. TIAA CREF Investment Management LLC raised its stake in shares of Insmed by 0.9% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 213,525 shares of the biopharmaceutical company’s stock valued at $3,664,000 after buying an additional 1,857 shares during the last quarter. Finally, Voya Investment Management LLC increased its stake in shares of Insmed by 9.3% in the 2nd quarter. Voya Investment Management LLC now owns 27,960 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 2,389 shares in the last quarter. 95.28% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This report was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.chaffeybreeze.com/2018/01/04/insmed-target-of-unusually-large-options-trading-insm.html.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply